Monday, May 18, 2009 12:23:22 PM
DVAX -
Dynavax Technologies Corporation (Nasdaq:DVAX), a clinical-stage biopharmaceutical company, today announced six abstracts presenting data at the American Thoracic Society (ATS) medical conference in San Diego, California May 15 - 20, 2009. Under a worldwide collaboration, Dynavax and its pharmaceutical partner AstraZeneca are discovering and developing novel therapies which represent a new strategy for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Dynavax's six abstracts can be viewed at http://www.thoracic.org/ and are as follows:
Non-Human Primate Airway Cells Incubated with Various Classes of CpG-Containing Immunostimulatory DNA Sequences Demonstrate High Levels of IFN-a Production Accompanied with Low to Absent Levels of TNF-a - Abstract #656 Poster Session: D33 - Asthma Therapeutics - Studies in Animal Models Wednesday, May 20, 2009, 8:15 am - 4:00 pm
Comparison of Different Classes of Immunostimulatory DNA Sequences Recognizing Toll-Like Receptor (TLR) 9 in In Vitro and In Vivo Studies - Abstract #654 Poster Session: D33 - Asthma Therapeutics - Studies in Animal Models Wednesday, May 20, 2009, 8:15 am - 4:00 pm
CD154/Intracellular Cytokine Staining of Antigen-Specific T Cell Responses Functions as a Biomarker for Immunostimulatory DNA Sequence (ISS)-Induced Disease Modification in a Chronic Mouse Asthma Model - Abstract #646 Poster session: C30 - Inflammatory and Immunological Models of Asthma Tuesday, May 19, 2009, 8:15 am - 4:00 pm
Discovery of Novel Plasma Biomarkers for Monitoring Therapeutic Efficacy of Tolamba(TM), an Immunotherapeutic Vaccine for Ragweed Allergic Rhinitis - Abstract #1150 Poster Session: C31 - Mechanism of Inflammation in the Airway Monday, May 18, 2009, 8:15 am - 10:45 am
Allergen-Specific CD154 and Intracellular Cytokine Expression Is a Sensitive Biomarker of Th1/Th2 Balance Applicable for Measurement of Human T Cell Responses to Therapeutic Interventions - Abstract #3584 Poster Session: B21 - Airway Inflammation: New Information About Mediators and Biomarkers Tuesday, May 19, 2009, 8:15 am - 4:00 pm
ISS-induced Effects on a Population of CD11c+, PDCA-1-, CD11bhigh, GR-1mod, MHC Class IIlow (immature DC-like ) Cells in the Airways of Ragweed-Allergic Mice - Abstract #1066 Poster Session: C32 - Immune Cellular Network in Lung Inflammation Tuesday, May 19, 2009, 8:15 am - 4:00 pm
About the AstraZeneca Collaboration
In September 2006, Dynavax and AstraZeneca entered into a potential $136 million research and license agreement to discover, develop, and commercialize novel therapies for the treatment of asthma and COPD. Dynavax's Toll-like Receptor 9 (TLR9) agonist products are based on its proprietary Immunostimulatory sequences (ISS), which are short DNA sequences that specifically target TLR9 to stimulate the innate immune response.
(
transmitted @_bbb_)
Dynavax Technologies Corporation (Nasdaq:DVAX), a clinical-stage biopharmaceutical company, today announced six abstracts presenting data at the American Thoracic Society (ATS) medical conference in San Diego, California May 15 - 20, 2009. Under a worldwide collaboration, Dynavax and its pharmaceutical partner AstraZeneca are discovering and developing novel therapies which represent a new strategy for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Dynavax's six abstracts can be viewed at http://www.thoracic.org/ and are as follows:
Non-Human Primate Airway Cells Incubated with Various Classes of CpG-Containing Immunostimulatory DNA Sequences Demonstrate High Levels of IFN-a Production Accompanied with Low to Absent Levels of TNF-a - Abstract #656 Poster Session: D33 - Asthma Therapeutics - Studies in Animal Models Wednesday, May 20, 2009, 8:15 am - 4:00 pm
Comparison of Different Classes of Immunostimulatory DNA Sequences Recognizing Toll-Like Receptor (TLR) 9 in In Vitro and In Vivo Studies - Abstract #654 Poster Session: D33 - Asthma Therapeutics - Studies in Animal Models Wednesday, May 20, 2009, 8:15 am - 4:00 pm
CD154/Intracellular Cytokine Staining of Antigen-Specific T Cell Responses Functions as a Biomarker for Immunostimulatory DNA Sequence (ISS)-Induced Disease Modification in a Chronic Mouse Asthma Model - Abstract #646 Poster session: C30 - Inflammatory and Immunological Models of Asthma Tuesday, May 19, 2009, 8:15 am - 4:00 pm
Discovery of Novel Plasma Biomarkers for Monitoring Therapeutic Efficacy of Tolamba(TM), an Immunotherapeutic Vaccine for Ragweed Allergic Rhinitis - Abstract #1150 Poster Session: C31 - Mechanism of Inflammation in the Airway Monday, May 18, 2009, 8:15 am - 10:45 am
Allergen-Specific CD154 and Intracellular Cytokine Expression Is a Sensitive Biomarker of Th1/Th2 Balance Applicable for Measurement of Human T Cell Responses to Therapeutic Interventions - Abstract #3584 Poster Session: B21 - Airway Inflammation: New Information About Mediators and Biomarkers Tuesday, May 19, 2009, 8:15 am - 4:00 pm
ISS-induced Effects on a Population of CD11c+, PDCA-1-, CD11bhigh, GR-1mod, MHC Class IIlow (immature DC-like ) Cells in the Airways of Ragweed-Allergic Mice - Abstract #1066 Poster Session: C32 - Immune Cellular Network in Lung Inflammation Tuesday, May 19, 2009, 8:15 am - 4:00 pm
About the AstraZeneca Collaboration
In September 2006, Dynavax and AstraZeneca entered into a potential $136 million research and license agreement to discover, develop, and commercialize novel therapies for the treatment of asthma and COPD. Dynavax's Toll-like Receptor 9 (TLR9) agonist products are based on its proprietary Immunostimulatory sequences (ISS), which are short DNA sequences that specifically target TLR9 to stimulate the innate immune response.
(
transmitted @_bbb_)
posts are IMHO // either news - with LINK
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
